Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 2005 Oct 31;102(45):16257–16262. doi: 10.1073/pnas.0508521102

Epidermal growth factor receptor signaling is required for normal ovarian steroidogenesis and oocyte maturation

Michelle Jamnongjit 1, Arvind Gill 1, Stephen R Hammes 1,*
PMCID: PMC1283479  PMID: 16260720

Abstract

The midcycle luteinizing hormone (LH) surge triggers several tightly linked ovarian processes, including steroidogenesis, oocyte maturation, and ovulation. We designed studies to determine whether epidermal growth factor receptor (EGFR)-mediated signaling might serve as a common regulator of these activities. Our results showed that EGF promoted steroidogenesis in two different in vitro models of oocyte-granulosa cell complexes. Inhibition of the EGFR kinase prevented EGF-induced steroidogenesis in these in vitro systems and blocked LH-induced steroidogenesis in intact follicles primed with pregnant mare serum gonadotropin. Similarly, inhibition of the EGFR kinase attenuated LH-induced steroidogenesis in MA-10 Leydig cells. Together, these results indicate that EGFR signaling is critical for normal gonadotropin-induced steroidogenesis in both male and female gonads. Interestingly, inhibition of metalloproteinase-mediated cleavage of membrane-bound EGF moieties abrogated LH-induced steroidogenesis in ovarian follicles but not MA-10 cells, suggesting that LH receptor signaling activates the EGFR by different mechanisms in these two models. Finally, steroids promoted oocyte maturation in several ovarian follicle models, doing so by signaling through classical steroid receptors. We present a model whereby steroid production may serve as one of many integrated signals triggered by EGFR signaling to promote oocyte maturation in gonadotropin-stimulated follicles.

Keywords: ovary, nongenomic, progesterone


Female fertility requires ordered follicular development and growth that ultimately leads to ovulation of mature oocytes in response to a midcycle luteinizing hormone (LH) surge. LH triggers multiple processes within the ovary that are all critical for normal ovulation, including steroidogenesis, cumulus-cell expansion, and oocyte maturation. Understanding the signaling pathways induced by LH in the ovary is therefore essential for appreciating how these activities relate to one another. Several pieces of evidence have implicated epidermal growth factor receptor (EGFR) signaling as a potential central pathway coordinating these important LH-mediated events.

First, EGF triggers steroidogenesis in gonadal cells, including Leydig cell lines (1, 2) and possibly granulosa cells (3). Whereas EGF promotes steroidogenesis in these models, an essential role for EGF and the EGFR in regulating gonadotropin-induced steroidogenesis has not been established.

Second, the EGFR regulates oocyte maturation (4, 5). Maturation refers to the meiotic progression of oocytes from prophase I to metaphase II that is required for normal ovulation and fertilization. LH triggers secretion of EGF molecules, which, in turn, signal in a paracrine fashion through the EGFR to stimulate cumulus-cell expansion and oocyte maturation. Notably, EGF cannot directly trigger maturation of denuded oocytes, suggesting that secondary messengers induced by EGFR signaling in the cumulus cells are required for meiotic progression.

Finally, in contrast to EGF, testosterone and estradiol can promote maturation of denuded mouse oocytes held in meiotic arrest in vitro (6). This process is transcription-independent and may be regulated by classical steroid receptors. Although steroids are established physiologic mediators of maturation in frogs and fish (7-10), their role in regulating mammalian-oocyte maturation is controversial. Furthermore, although steroids promote mouse-oocyte maturation in vitro, the physiologic relevance of steroid-mediated maturation in mammals has needed confirmation using models whereby oocytes are held in meiotic arrest by surrounding follicular cells.

These earlier studies raise the possibility that EGFR-mediated signaling may trigger steroidogenesis, which in turn contributes to oocyte maturation. In this study, we used several models to examine EGF-mediated steroidogenesis and maturation, including (i) cultures of oocyte-granulosa cell complexes (OGCs), which are isolated from preantral follicles in 12-day-old mice and grown to meiotic competence; (ii) meiotically competent oocyte-cumulus cell complexes (OCCs), which are isolated from 21- to 24-day-old mice and used immediately; and (iii) intact preovulatory follicles from mice primed with pregnant mare serum gonadotropin (PMSG). In each model, EGF promoted steroid production. In addition, gonadotropin-induced steroidogenesis was regulated in both ovarian follicles and Leydig cells by EGFR-mediated signaling, although the mechanisms activating these receptors appeared different in the two systems. Finally, EGFR signaling mediated sufficient steroid production to promote oocyte maturation in oocyte-granulosa cell models.

Materials and Methods

Steroid Production and Oocyte Maturation in Cultures of OGCs. OGCs were isolated (11) from 12-day-old C57BL/6J × SJL/J F1 mice (The Jackson Laboratory) by using Waymouth's MB752/1 medium (Invitrogen). EGF-mediated steroid production was measured after 10 days of culture. OGCs were washed twice with Waymouth's medium containing 3 mg/ml BSA and 5% FBS, followed by incubation with 20 ng/ml EGF (Becton Dickinson). OGCs were placed at 37°C with 5% O2,5%CO2, and 90% N2. Medium and cells were collected at 16 h, steroids were extracted (12), and RIAs were performed to detect steroids (MP Biomedicals, Irvine, CA). For maturation assays, OGCs were cultured for 10 days and then incubated at 37°C for 16 h with steroid or EGF at the indicated concentrations. Maturation was scored by denuding OGCs and examining oocytes for germinal-vesicle breakdown (GVBD). Results were verified by blinding individuals scoring for GVBD.

Steroid Production and Oocyte Maturation in OCCs. Ovaries from unprimed 21- to 24-day-old (C57BL/6J × SJL/J) F1 mice were placed into M2 medium (Chemicon) containing 200 μM 3-isobutyl-1-methylxanthine (IBMX, Calbiochem). Large follicles were punctured with 30-gauge needles, and OCCs were harvested by aspiration with pulled-glass pasteur pipettes. OCCs were washed with M2 and allocated into four-well culture dishes containing M16/IBMX at 37°C. OCCs were pretreated with EGFR kinase inhibitor AG1478 (Calbiochem), steroid receptor antagonists, or vehicle for 30 min before and throughout the addition of stimulators. Concentrations of DMSO or ethanol were 0.1%. Maturation (GVBD) of denuded oocytes was scored at 8 h. Medium and cells were collected for steroid detection by RIA.

Steroid Production and Oocyte Maturation in Preovulatory Follicles. Twenty-one- to 28-day-old C57BL/6J mice (The Jackson Laboratory) were injected with 5 IU of PMSG (Sigma) into the peritoneum. Follicles were isolated 44-48 h after PMSG injection by puncturing the ovaries with 30-gauge needles. Intact follicles >400 μ were selected, washed in M2, and placed in M16 medium and incubated at 37°C for 6 h with 3 μg/ml LH (Sigma), 200 ng/ml EGF, or 20 μM 22R-hydroxycholesterol (Steraloids, Newport, RI). GVBD of denuded oocytes was assessed and steroids measured by RIA after extraction from the medium and cells. Follicles were pretreated with AG1478, Galardin (Calbiochem), or vehicle for 30 min before and after adding stimulators.

Steroid Production in MA-10 Cells. The MA-10 mouse Leydig tumor cell line (provided by M. Ascoli, University of Iowa, Iowa City, IA) was grown in Waymouth's MB752/1 medium supplemented with 15% horse serum, 100 units/ml penicillin, and 0.1 mg/ml streptomycin under 5% CO2. Cells were put in 24-well plates 48 h before the experiments. On the day of the study, the cells were washed with PBS and placed in serum-free medium plus 20 mM Hepes and 3 mg/ml BSA. The cells were pretreated with AG1478, Galardin, or DMSO for 30 min before and throughout the addition of 3 μg/ml LH or 20 μM 22R-hydroxycholesterol. Medium was collected at 4 h, and steroids were extracted and measured by RIA.

Steroidogenic Acute Regulatory (StAR) Protein and CYP11A1 Immunoblotting. Fifteen OCCs were placed in M-16 medium with or without 20 ng/ml EGF and incubated at 37°C for 16 h. OCCs were collected and placed in 2× SDS buffer, pH 6.8, plus 10% β-mercaptoethanol. MA-10 cells were plated in six-well plates 24 h before treatment with 200 ng/ml EGF. After 4 h, 400 μlof2× SDS buffer plus 10% β-mercaptoethanol was added and the cells sheared with 25-gauge needles. Lysates were separated by electrophoresis and proteins transferred to Immobilon-P membranes (Millipore). The membranes were probed with rabbit anti-StAR (provided by D. M. Stocco, Texas Tech University Health Sciences Center, Lubbock, TX) and rabbit anti-CYP11A1 (provided by B. C. Chung, Institute of Molecular Biology, Taipei, Taiwan) antibodies.

Ovarian Steroid Levels. Steroid levels were measured in 8-week-old C57BL/6 mice maintained on a 12/12 light/dark cycle and tracked by vaginal cytology through a minimum of two estrous cycles. Animals were killed 2 h before the start of the dark cycle, ovaries were removed, and steroids were extracted and measured by RIA.

Immunofluorescence. Immunofluorescence was performed as described in ref. 13. Denuded oocytes from 4-week-old C57BL/6 mice were fixed in 2% paraformaldehyde and permeabilized with 0.1% Triton X-100. Primary antibody concentrations were 0.4 μg/ml for rabbit anti-progesterone receptor (C-19) and rabbit anti-androgen receptor (C-19) (Santa Cruz Biotechnology) and 2 μg/ml rabbit for the anti-estrogen receptor β (Affinity BioReagents, Golden, CO). For controls, the anti-androgen and -progesterone receptor antibodies were preincubated with their target peptides for 16 h. The secondary antibody anti-rabbit Alexa Fluor 488 (Molecular Probes) was used at 8 μg/ml. Images were visualized by using an Optiphot microscope (Nikon) with a UV light source and filter for fluorescein.

Steroid-Extraction Experiment. OCCs (≈150) were placed in M16 with 200 μM IBMX and 20 ng/ml EGF for 16 h at 37°C. Medium was collected, centrifuged at 0.8 relative centrifugal force to remove cells, and added to newly harvested OCCs in four conditions: (i) unmodified, (ii) treated with 20 μM AG1478, (iii) run through a Sep-Pak (Waters) cartridge to remove steroids, and (iv) both Sep-Pak and AG1478 treatment. Sep-Paks removed 95% of the steroid from the medium; however, they may also remove other hydrophobic molecules regulating oocyte maturation. Maturation (GVBD) was scored after 8 h.

Results

EGF Promotes Steroidogenesis in Oocyte-Granulosa Cell Cultures and OCCs by Signaling Through the EGFR. Steroid production in a growing oocyte/follicle cell model system was examined by using cultures of OGCs isolated from preantral follicles of 12-day-old mice (11). To determine whether EGF could stimulate steroid production, 10-day-old OGC cultures were incubated with 20 ng/ml EGF for 16 h. EGF increased progesterone, testosterone, and estradiol levels by 6-fold (absolute concentration ≈10 ng/ml), 3-fold (absolute concentration ≈6 ng/ml), and 2-fold (absolute concentration ≈4 ng/ml), respectively, relative to mock-treated cells (Fig. 1A).

Fig. 1.

Fig. 1.

EGF induces steroid production in OGCs. (A) EGF stimulates steroidogenesis in OGCs. After 10 days of culture, ≈120 OGCs were incubated for 16 h at 37°C with 20 ng/ml EGF, and medium steroid content was measured. Fold-induction was normalized to OGCs treated with 0.1% ethanol. Each bar is the average ± SD (n = 3). (B) Blocking the EGFR kinase inhibits EGF-stimulated steroid production in OCCs. OCCs (n = 30) were incubated with DMSO or 20 ng/ml EGF in the presence or absence of 20 μM AG1478. Steroid content was measured at 16 h. Similar results were seen in three experiments. (C) EGF increases StAR expression in MA-10 Leydig cells but not in OCCs. (D) EGF does not alter CYP11A1 protein levels in OCCs. OCCs (≈25) were incubated with 20 ng/ml EGF for 16 h, and MA-10 cells were incubated with 200 ng/ml EGF for 4 h. CYP11A1/StAR proteins were detected by Western blot.

The results of tests using OGC cultures were confirmed by using OCCs. Whereas OGCs are cultured from preantral follicles for 10 days before the oocytes are meiotically competent, OCCs are taken from 21- to 24-day-old prepubertal mice and used immediately after isolation. Similar to the results with cultured OGCs, EGF increased progesterone production in freshly isolated OCCs by ≈8-fold (progesterone ≈800 pg/ml) relative to mock treated OCCs (progesterone ≈100 pg/ml) at 8 h. EGF-mediated steroid production required an active EGFR, because the specific EGFR kinase inhibitor AG1478 abrogated EGF-induced progesterone secretion in OCCs (Fig. 1B). Notably, AG1478 almost completely blocks EGF-induced phosphorylation of the EGFR under these conditions (4).

EGF-Induced Steroidogenesis in OCCs Does Not Require Changes in Steroidogenic Acute Regulatory Protein or CYP11A1 Expression. In some cells, EGF-induced steroidogenesis is regulated by increased StAR protein expression (1). StAR is the primary regulator of cholesterol transport into the mitochondria, where the steroid precursor is then converted by CYP11A1 (side-chain cleavage enzyme) to pregnenolone. To determine whether EGF increased StAR or CYP11A1 protein expression, freshly isolated OCCs were incubated with EGF for 16 h, and cell lysates were analyzed for StAR and CYP11A1 expression by Western blot. As predicted in ref. 1, StAR expression increased dramatically in MA-10 Leydig cells in response to EGF (Fig. 1C). In contrast, neither StAR (Fig. 1C) nor CYP11A1 (Fig. 1D) expression were altered in EGF-treated OCCs relative to mock-treatment. This result suggests that EGF-induced steroidogenesis in OCCs may rely on posttranslational activating modifications of StAR and/or CYP11A1 rather than increased protein expression.

LH-Mediated Steroidogenesis in Ovarian Follicles Requires Cleavage of Membrane-Bound EGF Family Members and Activation of the EGFR. Preovulatory follicles from PMSG-primed mice were isolated and stimulated for 6 h with LH, resulting in a 10-fold increase in progesterone production (Fig. 2A). In contrast, EGF was less potent than LH, triggering a 3-fold increase in progesterone production (Fig. 2A). Inhibition of EGF signaling with the EGF receptor kinase inhibitor AG1478 prevented the LH-induced increase in progesterone production (Fig. 2B), suggesting that EGFR signaling is critical for normal LH-mediated steroidogenesis in ovarian follicles.

Fig. 2.

Fig. 2.

EGFR signaling is necessary for gonadel LH-induced steroidogenesis. (A) LH is a more potent inducer of steroidogenesis than is EGF. (B) LH-induced steroid production is inhibited by blocking EGFR signaling and MMP activity. (C) Fifteen ovarian follicles were incubated with DMSO, 3 μg/ml LH, or 200 ng/ml EGF with or without 20 μM AG1478 (B) or Galardin (C). Medium progesterone content was measured at 6 h. Similar results were observed in six experiments. (D) Inhibition of MMPs does not affect StAR-independent steroidogenesis. Fifteen follicles were incubated with DMSO or 20 μM 22R-hyroxycholesterol in the presence or absence of 20 μM Galardin. Medium progesterone content was measured at 6 h. This experiment was performed twice, with similar results. (E) Steroid production in MA-10 Leydig cells. The cells were incubated with vehicle, 3 μg/ml LH, or 20 μM 22R-cholesterol with or without 20 μM AG1478 or Galardin. Medium progesterone content was measured at 4 h. Bars represent the average (±SD) (n = 3). Identical results were seen in three experiments.

G protein-coupled receptors activate EGFR signaling by several mechanisms (14, 15). For example, stimulation of the Gαs-coupled β2-adrenergic receptor activates membrane-bound matrix metalloproteinases (MMPs) that cleave heparin-bound EGF (HB-EGF) from the cell surface to autoactivate the EGFR (16). MMPs may also activate other members of the membrane-bound EGF family, including amphiregulin (17). Because MMPs are critical for numerous ovarian functions (18) and because the LH receptor also signals via Gαs, the role of membrane-bound EGF family members in regulating LH-induced follicular steroidogenesis was examined. Inhibition of MMP activity was achieved by coincubating LH-treated follicles with the MMP inhibitor Galardin. Galardin blunted LH-induced progesterone production (Fig. 2C), implicating MMPs and membrane-bound EGFs as important regulators of gonadotropin-induced steroidogenesis. Galardin's inhibitory effects could be reversed by EGF (Fig. 2C), confirming that Galardin acts upstream of the EGFR. Furthermore, Galardin did not alter StAR-independent progesterone production from 22R-hydroxycholesterol (Fig. 2D), confirming that the compound was not a general inhibitor of steroidogenesis and that MMP- and EGFR-mediated steroid production is likely regulated by increased StAR activity.

Normal LH-Mediated Steroidogenesis in MA-10 Leydig Cells Requires Activation of the EGFR but Not Membrane-Bound EGFs. To determine whether EGFR signaling might be a universal mechanism for regulating gonadal steroidogenesis, we examined LH-induced steroidogenesis in the MA-10 mouse Leydig cell line. LH triggered a 10-fold increase in progesterone production at 4 h (Fig. 2E). Similar to ovarian follicles, LH-induced progesterone production was abrogated by the EGFR kinase inhibitor AG1478; however, unlike follicles, gonadotropin-induced steroidogenesis in MA-10 cells was unaffected by the MMP inhibitor Galardin. Addition of 22R-hydroxycholesterol rescued the suppressive effects of AG1478 on LH-mediated progesterone production (Fig. 2E), confirming that, as in the ovary, EGFR-mediated steroid production in Leydig cells is regulated by increased StAR activity (1).

Steroids Promote Oocyte Maturation in Oocyte-Granulosa Cell Models. EGFR activation is required for oocyte maturation (4). Because the EGFR is also necessary for LH-induced steroidogenesis, and because steroids trigger maturation of denuded mouse oocytes (6), the regulation of EGFR-induced oocyte maturation might, therefore, involve steroids. To determine the steroids that might be important in vivo, ovarian steroid content in cycling mice was measured. The estrous cycles of 8-week-old female mice were tracked by vaginal cytology, ovaries were removed on the indicated days, and steroid content was measured by RIA. Levels of progesterone, testosterone, and estradiol all increased at ovulation and remained high throughout diestrus II (Fig. 3). Ovarian progesterone content was ≈100-fold higher than that of testosterone and estradiol; thus, focus was placed on progesterone as a potential physiologic mediator of oocyte maturation.

Fig. 3.

Fig. 3.

Ovarian steroid levels in cycling mice. On the indicated days, steroids were extracted from ovaries and measured by RIA. Bars represent an average (±SD) of 10-12 animals. (A) Testosterone and estradiol levels. (B) Progesterone levels.

In cultured OGCs, where oocytes are held in meiotic arrest by the surrounding granulosa cells, both progesterone and testosterone promoted oocyte maturation as well as did EGF (Fig. 4A). Progesterone similarly triggered oocyte maturation in freshly isolated OCCs. In fact, progesterone promoted maturation more rapidly than EGF, suggesting that steroids may act downstream of EGFR signaling (Fig. 4B). Furthermore, unlike EGF, progesterone did not promote cumulus cell expansion in OCCs (Fig. 4D), implying that it acts directly on oocytes rather than on cumulus cells.

Fig. 4.

Fig. 4.

Steroids are sufficient to promote oocyte maturation. (A) Progesterone and testosterone promote maturation in cultured OGCs. OGCs were grown for 10 days and incubated with 250 nM steroid or 20 ng/ml EGF for 16 h. The y axis indicates the percent of oocytes that had undergone GVBD. Similar results were seen in three experiments. (B) Time course for oocyte maturation. OCCs were incubated with 250 nM progesterone or 20 ng/ml EGF, and oocytes were scored for GVBD at the indicated times. (C) Steroids rescue AG1478-mediated inhibition of maturation. OCCs were treated with AG1478 or DMSO for 30 min before and after the addition of 20 ng/ml EGF. Progesterone (250 nM) was added to rescue inhibition. GVBD was scored at 6 h. Progesterone content is shown below the graph. Twenty OCCs were used in each condition and the experiment repeated twice. (D) Steroids do not promote cumulus-cell expansion in OCCs. Cells were placed in medium containing EtOH, 250 nM progesterone, or 20 ng/ml EGF. Images were taken at 16 h. (E) EGF-mediated steroid production is sufficient to promote oocyte maturation. OCCs (n = 150) were incubated with 20 ng/ml EGF for 16 h. Medium was collected and added to newly harvested OCCs in four conditions: (i) unmodified, (ii) with 20 μM AG1478, (iii) with steroid extraction, and (iv) with AG1478 and steroid extraction. GVBD was scored at 8 h. Results are the average (±range) of two experiments.

Progesterone Is Sufficient to Promote Oocyte Maturation in the Absence of EGFR Signaling. The EGFR kinase inhibitor AG1478 attenuates EGF-induced maturation in OCCs (5). Because steroid production appears to be downstream of EGFR signaling, progesterone should overcome AG1478-mediated inhibition of meiosis. OCCs were, therefore, treated with EGF, EGF plus AG1478, or EGF plus AG1478 and progesterone. The progesterone completely rescued AG1478-mediated inhibition of oocyte maturation (Fig. 4C), confirming that steroid-triggered maturation occurs independent and downstream of EGFR signaling. Corresponding steroid levels verified that AG1478 inhibited progesterone production.

To determine whether EGF-induced steroidogenesis was sufficient to promote maturation, OCCs were treated with EGF for 16 h. The surrounding medium, which contained EGF and steroids, was then collected and added to newly isolated OCCs under four different conditions: (i) The medium was left unmodified, resulting in 100% maturation (Fig. 4E), likely triggered by both steroids and EGF in the medium. (ii) Medium was added to OCCs in the presence of the EGFR kinase inhibitor AG1478, causing 94% maturation, likely regulated by steroids and/or other EGF-induced factors. (iii) Steroids, but not EGF, were extracted from the medium, resulting in 100% maturation. (iv) Steroids were extracted and AG1478 was added, thus inhibiting both steroid- and EGFR-mediated signaling. Under this condition, oocyte maturation was significantly impaired. These results provide proof-in-principle that EGF-induced steroid production is sufficient to mediate oocyte maturation.

Progesterone Promotes Oocyte Maturation in Intact Follicles. Steroid-mediated maturation was examined in preovulatory follicles from PMSG-primed mice. Both progesterone and testosterone promoted oocyte maturation in the preovulatory follicles (Fig. 5A). In addition, progesterone-mediated maturation was unaffected by AG1478 (data not shown) or Galardin (Fig. 5B), again indicating that progesterone acts downstream of the EGFR.

Fig. 5.

Fig. 5.

Steroids promote maturation in follicles. (A) Fifteen follicles were incubated with 250 nM steroid or 3 μg/ml LH for 6 h and scored for GVBD. A representative graph is shown from three experiments. (B) Steroids rescue Galardin-mediated inhibition of maturation in follicles. Follicles were treated with Galardin or DMSO for 30 min before and throughout the addition of 3 μg/ml LH. Progesterone (250 nM) rescued inhibition. GVBD was scored after 6 h. Progesterone content is shown below the graph. The experiment was performed twice with nearly identical results.

Classical Steroid Receptors Mediate Steroid-Induced Maturation. Steroid-induced maturation of denuded mouse oocytes may be mediated by classical steroid receptors (6). To provide additional insight into this issue, steroid-receptor expression was examined in denuded oocytes by using immunofluorescence. Intracellular progesterone, androgen, and estrogen β-receptors were detected throughout oocytes, as indicated by green fluorescence (Fig. 6A). The α-form of the estrogen receptor (ER) was undetectable by using two different antibodies (data not shown), indicating that the β-form predominates in oocytes.

Fig. 6.

Fig. 6.

Classical steroid receptors are expressed in mouse oocytes. (A) Oocytes were incubated with antibodies against androgen receptor (AR), ERβ, and progesterone receptor (PR). Immunofluorescence demonstrates the expression of all three receptors. (B) Oocytes were incubated with primary antibodies pretreated with peptide to which they were directed (AR and PR) or no primary antibody (ERβ). (C) White-light images of the oocytes in B.

Pharmacologic experiments were next performed to determine whether classical receptors mediated steroid-induced maturation in OCCs. Care was taken to use agonists that could not be metabolized. First, the synthetic progestin promegestone (RU5020) potently promoted oocyte maturation, and its effects were reduced by the progesterone-receptor antagonist mifepristone (Table 1). Estradiol rescued this inhibition, indicating that the antagonist blocked the progesterone receptor specifically. Second, faslodex (ICI 182, 780), a nonselective ERα and ERβ antagonist, blocked estradiol-mediated maturation, and this inhibition was rescued by promegestone. Finally, the androgen receptor antagonist flutamide blocked maturation induced by dihydrotestosterone, and this inhibition was rescued by estradiol. These experiments support the concept that classical steroid receptors mediate steroid-triggered oocyte maturation.

Table 1. Classical steroid receptor antagonists inhibit steroid-triggered maturation in OCCs.

Receptor ETOH control, % Agonist (%) Inhibitor (%) Steroid rescue (%)
PR 20 Promegestone (90) Mifepristone (20) Estradiol (75)
ER 15 Estradiol (90) Faslodex (25) Promegestone (100)
AR 19 DHT (75) Flutamide (19) Estradiol (81)

Percentages represent percent of oocytes that have undergone GVBD after 8 h. OCCs were treated with agonist, agonist plus a corresponding antagonist (inhibitor), or agonist, antagonist, and an alternative steroid (Rescue). Antagonists were added 30 min before and throughout the addition of agonists. Concentrations were 100 nM for agonists, 2.5 μM for antagonists, and 250 nM for rescuing steroids. PR, progesterone receptor; AR, androgen receptor; ER, estrogen receptor.

Discussion

Our studies demonstrate that EGF signaling through the EGFR is sufficient to promote steroid production in two models of mouse OGCs. EGFR-mediated signaling is necessary for maximal gonadotropin-induced steroidogenesis in the ovary and testes, because the EGFR kinase inhibitor AG1478 ablated LH-induced steroidogenesis in ovarian follicles and MA-10 Leydig cells. Notably, because EGF was less potent than LH in promoting steroidogenesis in follicles, EGFR signaling appears necessary but not sufficient for maximal gonadotropin-induced steroid production.

Our studies also address the mechanisms by which LH-receptor signaling leads to EGFR activation. Based on past and present data, we propose the following model (Fig. 7): LH activates its receptor located on theca cells (20), resulting in the activation of MMPs and cleavage of membrane-bound EGFs. Soluble EGF molecules then bind to EGFRs on cumulus granulosa cells, and perhaps all follicular cells, to enhance steroid production. However, progesterone, the most abundantly produced steroid, likely comes primarily from granulosa cells that lack CYP17 and cannot metabolize the steroid. In contrast, MMPs do not regulate LH-induced steroidogenesis in MA-10 Leydig cells, suggesting that alternative mechanisms (14) activate the EGFR in these cells. These differences may reflect the greater role of paracrine signaling in the ovary, where multiple cell types are required for steroidogenesis.

Fig. 7.

Fig. 7.

Model for gonadotropin-induced oocyte maturation. LH binds to its receptors on theca cells. Activation of the LH receptor results in MMP-mediated cleavage of membrane-bound EGF molecules. Upon release, these EGFs then bind to EGFRs on cumulus cells (and likely others) to enhance the production of steroids and other factor(s) that promote oocyte maturation.

How does activation of the EGFR stimulate steroidogenesis? In Leydig cells, EGF increases the expression and activity of StAR protein (1). In ovarian follicles, EGFR-mediated steroidogenesis is also regulated by StAR, because Galardin blocked StAR-dependent LH-induced steroidogenesis but not StAR-independent steroid production from 22R-cholesterol. StAR-protein expression was unchanged by EGF in OCCs, suggesting that, in granulosa cells, StAR activity rather than expression is increased by EGFR signaling, perhaps due to posttranslational modifications, such as phosphorylation (21).

The consequences of EGFR-induced steroidogenesis are significant, because steroids mediate many ovarian functions. We demonstrate here that progesterone, testosterone, and estradiol trigger maturation in models where oocytes are held in meiotic arrest by surrounding follicular cells. Although other receptors might regulate steroid-triggered maturation in fish (22), mouse-oocyte maturation appears to be mediated by classical steroid receptors, because classical receptor antagonists blocked steroid-mediated maturation.

The EGFR regulates oocyte maturation (4, 5), but EGF cannot trigger maturation of denuded oocytes, implying that secondary messengers in cumulus cells regulate EGF-mediated maturation. The rapidity of progesterone-mediated maturation relative to EGF, the ability of progesterone to rescue AG1478- and Galardin-mediated inhibition of EGF- and LH-induced oocyte maturation, respectively, and the presence of sufficient steroid in the media of EGF-treated OCCs to trigger maturation confirm that steroids signal downstream of the EGFR to regulate meiosis (Fig. 7). Similar to Xenopus, several steroids promote oocyte maturation via their respective receptors in vitro, demonstrating redundancy in this important physiologic process. However, progesterone is the most abundant ovarian steroid in ovulating mice and, therefore, is likely the primary steroid regulating meiosis in vivo. Interestingly, administration of progesterone to ovulating primates enhances oocyte maturation (23), confirming progesterone's potential physiologic role in regulating maturation.

Blockade of follicular steroid production does not completely suppress gonadotropin-induced oocyte maturation (24, 25), suggesting that EGFR signaling promotes oocyte maturation by more than one mechanism. Pathways other than steroidogenesis that may promote maturation include EGF-mediated cumulus expansion, which disrupts cumulus cell-oocyte gap junctions (26, 27), and attenuation of G protein-mediated signals holding oocytes in meiotic arrest (28, 29). Each activation pathway may regulate different aspects of follicular and oocyte development. For example, steroid may enhance oocyte maturation in dominant follicles that contain the highest steroid concentrations (30).

Finally, steroid-mediated maturation may be important in disorders of androgen excess, such as polycystic ovarian syndrome (31), which is characterized by anovulation, unregulated follicle growth, and the absence of dominant follicles (32). Treatment with anti-androgens improves ovarian function in these patients (33, 34). Perhaps regulating EGFR or MMP activity in the ovary might similarly prove beneficial for women with androgen excess.

Acknowledgments

We thank Jean Wilson for his advice and John Eppig and Marilyn O'Brien for technical assistance in culturing OGCs. S.R.H. is a W. W. Caruth, Jr., Endowed Scholar in Biomedical Research. M.J. was funded, in part, by National Institutes of Health (NIH) Training Grant T32 GM07062-29. This work was supported by NIH Grant DK59913, March of Dimes Grant FY05-78, and Welch Foundation Grant I-1506.

Author contributions: M.J., A.G., and S.R.H. designed research; M.J. and A.G. performed research; M.J., A.G., and S.R.H. analyzed data; and M.J. and S.R.H. wrote the paper.

Conflict of interest statement: No conflicts declared.

Abbreviations: EGF, epidermal growth factor; EGFR, EGF receptor; ER, estrogen receptor; GVBD, germinal vesicle breakdown; LH, luteinizing hormone; MMP, matrix metalloproteinase; OCC, oocyte-cumulus cell complex; OGC, oocyte-granulosa cell complex; PMSG, pregnant mare serum gonadotropin; StAR, steroidogenic acute regulatory.

References

  • 1.Manna, P. R., Huhtaniemi, I. T., Wang, X. J., Eubank, D. W. & Stocco, D. M. (2002) Biol. Reprod. 67, 1393-1404. [DOI] [PubMed] [Google Scholar]
  • 2.Ascoli, M. & Segaloff, D. L. (1989) Ann. N.Y. Acad. Sci. 564, 99-115. [DOI] [PubMed] [Google Scholar]
  • 3.Jezova, M., Scsukova, S., Nagyova, E., Vranova, J., Prochazka, R. & Kolena, J. (2001) Anim. Reprod. Sci. 65, 115-126. [DOI] [PubMed] [Google Scholar]
  • 4.Park, J. Y., Su, Y. Q., Ariga, M., Law, E., Jin, S. L. & Conti, M. (2004) Science 303, 682-684. [DOI] [PubMed] [Google Scholar]
  • 5.Ashkenazi, H., Cao, X., Motola, S., Popliker, M., Conti, M. & Tsafriri, A. (2005) Endocrinology 146, 77-84. [DOI] [PubMed] [Google Scholar]
  • 6.Gill, A., Jamnongjit, M. & Hammes, S. R. (2004) Mol. Endocrinol. 18, 97-104. [DOI] [PubMed] [Google Scholar]
  • 7.Smith, D. M. & Tenney, D. Y. (1980) J. Reprod. Fertil. 60, 331-338. [DOI] [PubMed] [Google Scholar]
  • 8.Maller, J. L. & Krebs, E. G. (1980) Curr. Top. Cell. Regul. 16, 271-311. [DOI] [PubMed] [Google Scholar]
  • 9.Tian, J., Kim, S., Heilig, E. & Ruderman, J. V. (2000) Proc. Natl. Acad. Sci. USA 97, 14358-14363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hammes, S. R. (2004) Mol. Endocrinol. 18, 769-775. [DOI] [PubMed] [Google Scholar]
  • 11.Eppig, J. J. & Schroeder, A. C. (1989) Biol. Reprod. 41, 268-276. [DOI] [PubMed] [Google Scholar]
  • 12.Lutz, L. B., Cole, L. M., Gupta, M. K., Kwist, K. W., Auchus, R. J. & Hammes, S. R. (2001) Proc. Natl. Acad. Sci. USA 98, 13728-13733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Brown, R. L., Ord, T., Moss, S. B. & Williams, C. J. (2002) Biol. Reprod. 67, 981-987. [DOI] [PubMed] [Google Scholar]
  • 14.Pierce, K. L., Luttrell, L. M. & Lefkowitz, R. J. (2001) Oncogene 20, 1532-1539. [DOI] [PubMed] [Google Scholar]
  • 15.Herrlich, A., Daub, H., Knebel, A., Herrlich, P., Ullrich, A., Schultz, G. & Gudermann, T. (1998) Proc. Natl. Acad. Sci. USA 95, 8985-8990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Maudsley, S., Pierce, K. L., Zamah, A. M., Miller, W. E., Ahn, S., Daaka, Y., Lefkowitz, R. J. & Luttrell, L. M. (2000) J. Biol. Chem. 275, 9572-9580. [DOI] [PubMed] [Google Scholar]
  • 17.Thorne, B. A. & Plowman, G. D. (1994) Mol. Cell. Biol. 14, 1635-1646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Curry, T. E., Jr., & Osteen, K. G. (2003) Endocr. Rev. 24, 428-465. [DOI] [PubMed] [Google Scholar]
  • 19.Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C. & Ullrich, A. (1999) Nature 402, 884-888. [DOI] [PubMed] [Google Scholar]
  • 20.Peng, X. R., Hsueh, A. J., LaPolt, P. S., Bjersing, L. & Ny, T. (1991) Endocrinology 129, 3200-3207. [DOI] [PubMed] [Google Scholar]
  • 21.Jo, Y., King, S. R., Khan, S. A. & Stocco, D. M. (2005) Biol. Reprod. 73, 244-255. [DOI] [PubMed] [Google Scholar]
  • 22.Zhu, Y., Bond, J. & Thomas, P. (2003) Proc. Natl. Acad. Sci. USA 100, 2237-2242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Borman, S. M., Chaffin, C. L., Schwinof, K. M., Stouffer, R. L. & Zelinski-Wooten, M. B. (2004) Biol. Reprod. 71, 366-373. [DOI] [PubMed] [Google Scholar]
  • 24.Lieberman, M. E., Tsafriri, A., Bauminger, S., Collins, W. P., Ahren, K. & Lindner, H. R. (1976) Acta Endocrinol. 83, 151-157. [DOI] [PubMed] [Google Scholar]
  • 25.Yamashita, Y., Shimada, M., Okazaki, T., Maeda, T. & Terada, T. (2003) Biol. Reprod. 68, 1193-1198. [DOI] [PubMed] [Google Scholar]
  • 26.Eppig, J. J. (1994) Hum. Reprod. 9, 974-976. [DOI] [PubMed] [Google Scholar]
  • 27.Kanemitsu, M. Y. & Lau, A. F. (1993) Mol. Biol. Cell 4, 837-848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Mehlmann, L. M., Jones, T. L. & Jaffe, L. A. (2002) Science 297, 1343-1345. [DOI] [PubMed] [Google Scholar]
  • 29.Mehlmann, L. M., Saeki, Y., Tanaka, S., Brennan, T. J., Evsikov, A. V., Pendola, F. L., Knowles, B. B., Eppig, J. J. & Jaffe, L. A. (2004) Science 306, 1947-1950. [DOI] [PubMed] [Google Scholar]
  • 30.Teissier, M. P., Chable, H., Paulhac, S. & Aubard, Y. (2000) Hum. Reprod. 15, 2471-2477. [DOI] [PubMed] [Google Scholar]
  • 31.Dunaif, A. (1997) Endocr. Rev. 18, 774-800. [DOI] [PubMed] [Google Scholar]
  • 32.Nelson, V. L., Legro, R. S., Strauss, J. F., III, & McAllister, J. M. (1999) Mol. Endocrinol. 13, 946-957. [DOI] [PubMed] [Google Scholar]
  • 33.Gambineri, A., Pelusi, C., Genghini, S., Morselli-Labate, A. M., Cacciari, M., Pagotto, U. & Pasquali, R. (2004) Clin. Endocrinol. (Oxford) 60, 241-249. [DOI] [PubMed] [Google Scholar]
  • 34.Rittmaster, R. S. (1999) Endocrinol. Metab. Clin. North Am. 28, 409-421. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES